90417-38-2

Basic information

• Product Name: NU1025
• Synonyms: NU1025;8-HYDROXY-2-METHYL-4(3H)-QUINAZOLINONE;8-HYDROXY-2-METHYLQUINAZOLIN-4[3H]-ONE;8-HYDROXY-2-METHYLQUINAZOLINE-4-ONE;8-Hydroxy-2-methylquinazoline-4-one ,97%;8-hydroxy-2-methyl-1H-quinazolin-4-one;NSC 696807;4(3H)-Quinazolinone, 8-hydroxy-2-Methyl-
• CAS NO: 90417-38-2
• Molecular Formula: C9H8N2O2
• Molecular Weight: 176.17
• Product Categories: All Inhibitors;Inhibitors;Aromatics
• Mol File: 90417-38-2.mol
• Article Data: 9

Chemical Properties

• Melting Point: 253-258°C
• Boiling Point: 345.4°Cat760mmHg
• Flash Point: 162.7°C
• Appearance: off-white/solid
• Density: 1.42
• Vapor Pressure: 3.09E-05mmHg at 25°C
• Refractive Index: 1.677
• Storage Temp.: −20°C
• Solubility: DMSO: 35 mg/mL, soluble
• CAS DataBase Reference: NU1025(CAS DataBase Reference)
• NIST Chemistry Reference: NU1025(90417-38-2)
• EPA Substance Registry System: NU1025(90417-38-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 90417-38-2(Hazardous Substances Data)

Usage

Description

NU 1025 is an inhibitor of poly(ADP-ribose) polymerases (PARP) (IC50 = 400 nM). It enhances the cytotoxicity of γ-irradiation and certain anticancer drugs. NU 1025 is also used to study the regulation of deoxyribonucleic acid repair by PARP enzymes.

Chemical Properties

Off-White to Pale Yellow Solid

Uses

Different sources of media describe the Uses of 90417-38-2 differently. You can refer to the following data:
1. NU 1025 is an inhibitor of poly(ADP-ribose) polymerases (PARP) (IC50 = 400 nM). It enhances the cytotoxicity of γ-irradiation and certain anticancer drugs. NU 1025 is also used to study the regulation of deoxyribonucleic acid repair by PARP enzymes.[Cayman Chemical]
2. A potent inhibitor of poly (ADP-ribose) polymerase (PARP). Ki and IC50 values are 48 and 400 nM respectively
3. A potent inhibitor of poly (ADP-ribose) polymerase (PARP). Ki and IC50 values are 48 and 400 nM respectively.

Definition

ChEBI: A member of the class of quinazolines that is quinazolin-4(1H)-one substituted by a hydroxy group at position 8 and a methyl group at position 2. It has been shown to exhibit inhibitory activity against poly(ADP-ribose) polymerase.

Biological Activity

Novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP). K i and IC 50 values are 48 and 400 nM respectively.

InChI:InChI=1/C9H8N2O2/c1-5-10-8-6(9(13)11-5)3-2-4-7(8)12/h2-4,12H,1H3,(H,10,11,13)

Upstream product

• 90915-45-0 8-methoxy-2-methyl-4-oxo-3,4-dihydroquinazoline 
• 16064-27-0 8-methoxy-quinazolin-4(3H)-one 
• 3177-80-8 2-amino-3-methoxybenzoic acid 
• 4920-80-3 3-methoxy-2-nitrobenzoic acid 
• 16064-17-8 NU 1026 
• 54905-94-1 8-methoxy-2-methyl-4H-benzo[d][1,3]oxazin-4-one 
• 172462-98-5 2-N-Acetylamino-3-methoxybenzamide 
• 106782-78-9 3-methoxy-2-aminobenzamide 

Downstream Products

• 154288-10-5 4-chloro-8-hydroxy-2-methyl-quinazoline 

Relevant articles and documents

Studies towards hypoxia-activated prodrugs of PARP inhibitors

Poly(ADP-ribose)polymerase (PARP) inhibitors (PARPi) have recently been approved for the treatment of breast and ovarian tumors with defects in homologous recombination repair (HRR). Although it has been demonstrated that PARPi also sensitize HRR competent tumors to cytotoxic chemotherapies or radiotherapy, normal cell toxicity has remained an obstacle to their use in this context. Hypoxia-activated prodrugs (HAPs) provide a means to limit exposure of normal cells to active drug, thus adding a layer of tumor selectivity. We have investigated potential HAPs of model PARPi in which we attach a bioreducible “trigger” to the amide nitrogen, thereby blocking key binding interactions. A representative example showed promise in abrogating PARPi enzymatic activity in a biochemical assay, with a ca. 160-fold higher potency of benzyl phthalazinone 4 than the corresponding model HAP 5, but these N-alkylated compounds did not release the PARPi upon one-electron reduction by radiolysis. Therefore, we extended our investigation to include NU1025, a PARPi that contains a phenol distal to the core binding motif. The resulting 2-nitroimidazolyl ether provided modest abrogation of PARPi activity with a ca. seven-fold decrease in potency, but released the PARPi efficiently upon reduction. This investigation of potential prodrug approaches for PARPi has identified a useful prodrug strategy for future exploration.

NEUROLOGICALLY-ACTIVE COMPOUNDS

The present invention relates to neurologically-active compounds, being heterocyclic compounds having two fused 6-membered rings with a nitrogen atom at position 1 and a hydroxy or mercapto group at position 8 with at least one ring being aromatic. Also disclosed are processes for the preparation of these compounds and their use as pharmaceutical or veterinary agents, in particular for the treatment of neurological conditions, more specifically neurodegenerative conditions such as Alzheimer's disease.

Resistance-modifying agents. 5.1 Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)

Clinical studies concerning the role of poly(ADP-ribose) polymerase (PARP) in the repair of drug- and radiation-induced DNA damage have been impeded by the poor solubility, lack of potency, and limited specificity of currently available inhibitors. A seri